Navigation Links
Isis Pharmaceuticals Conference Call Notice
Date:6/30/2008

-- Tuesday, July 1, 2008

-- 10:00 a.m. EDT, 7:00 a.m. PDT

-- 877-548-7901

-- http://www.isispharm.com

SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals (Nasdaq: ISIS) will conduct a conference call at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, July 1, to discuss results of the TV-1102 clinical trial and the ATL / TEVA / Isis relationship.

-- ATL and TEVA announced clinical data on TV-1102 demonstrating positive disease benefit in patients with multiple sclerosis

-- Isis to received $1.3 million of ATL's $4 million milestone payment from TEVA
-- Isis may receive one third of up to $100 million in milestones

To view the press release

Please visit http://www.isispharm.com or http://www.antisense.com.au/_home.asp to view the release titled:

Teva Pharmaceuticals & Antisense Therapeutics Announce That ATL/TV 1102,

a Novel Drug for the Treatment of Relapsing Remitting Multiple Sclerosis

Demonstrated Significant Reduction in Disease Activity

To access this call via telephone

Please call 1-877-548-7901 in the United States, five to ten minutes prior to the call. You will be asked to provide your name and indicate that you wish to participate in the Isis Pharmaceuticals' conference call hosted by Dr. Stanley Crooke.

To access this call via internet:

Please go to the Isis website at http://www.isispharm.com five to te
'/>"/>

SOURCE Isis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Denmark and ATLANTA , August ... the US Food and Drug Administration (FDA) cleared the MagVita ... in adult patients who have failed to receive satisfactory improvement ... a non-invasive technique for stimulating neural tissue in the part ... Disorder. The procedure has been proven safe and effective and ...
(Date:8/28/2015)... LONDON , August 28, 2015 ... approach seamlessly connects people, technologies and care ... improving outcomes and the cost of healthcare delivery ... AEX: PHIA) today announced its presence at  ESC Congress 2015 , ... Heart Model A.I. , EchoNavigator and IntelliSpace Cardiovascular, that connect ...
(Date:8/27/2015)... -- Biosimilars are not generics and the Biologics ... Drug Administration (FDA) for recognizing that each biosimilar ... issued today. The FDA,s draft guidance on nonproprietary ... for biological products to bear a nonproprietary name ... the agency,s thinking that "there is a need ...
Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2
... Ontario, July 18, 2011 CardioGenics Holdings Inc. (CGNH.OB) ... available for on-demand viewing at the RetailInvestorConferences website. ... will be available 24/7 for 90 days. Investors may ... the next three weeks. About CardioGenics ...
... July 18, 2011 Coronado Biosciences, Inc. (the "Company"), ... immunotherapy agents for the treatment of autoimmune diseases and ... on Form 10 with the Securities and Exchange Commission ... the purpose of becoming a reporting company.  The filing ...
Cached Medicine Technology:CardioGenics Holdings Inc. Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com 2Coronado Biosciences Files to Become a Public Reporting Company 2
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... Brands like ... with zero standard shipping costs. , “Before, a threshold of $49.00 was required ... select brands and items qualify for free standard shipping for customers regardless of the ...
(Date:8/29/2015)... ... 2015 , ... People who have heart or lung diseases, ... are at higher risk from wildfire smoke especially in Calgary, Alberta.Those with existing ... (arrhythmia or irregular heartbeat) are also sensitive to air pollution. , Tiny ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health Sciences announced today ... and Arterosil HP, and that all claims and counterclaims have been irrevocably dismissed. ... (VHS) in the United States District Court for the Southern District of Texas ...
(Date:8/28/2015)... ... August 28, 2015 , ... An online provider of ... make the purchase of CPAP equipment more affordable by offering shipping at no cost ... of CPAP products and orders of any size. My Cpap Store is located in ...
(Date:8/28/2015)... Angeles, CA (PRWEB) , ... August 28, 2015 , ... ... endless journey that local pizza maker Paul LaRocco has gone through to open a ... city approval and permitting process tends to take several months, but the current process, ...
Breaking Medicine News(10 mins):Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:My Cpap Store Now Offering Delivery Special 0 Cost to You 2Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2
... a large analysis of men participating in a prostate drug ... correlation between coronary artery disease and prostate cancer, suggesting the ... heart disease is a risk factor for prostate cancer, the ... as weight loss, exercise and a healthy diet, which are ...
... whose kids went to high-quality day care were more involved in ... poorer quality day care or no day care, new research finds. ... Development , researchers examined information on more than 1,300 children ranging ... quality of child care was evaluated periodically over 3.5 years. ...
... at Virginia Commonwealth University Medical Center,s VCU Massey ... (Richmond, VA) and Old Dominion University (Norfolk, VA) ... protein (WT1) results in downregulation of CD97 gene ... the characteristic invasiveness exhibited by glial tumor cells. ...
... (HealthDay News) -- Surgery can significantly improve seizure control ... to a study stretching over 26 years. ... surgery patients in that it spans three decades, during ... said Dr. Cynthia Harden, chief of the division of ...
... Reporter , MONDAY, Feb. 6 (HealthDay News) -- New ... those found on the tongue -- that can "taste" fructose. ... and beverages. Nutrition experts have warned that Americans take in ... their concerns. In lab studies of pancreas cells from ...
... , MONDAY, Feb. 6 (HealthDay News) -- People,s ... can vary greatly among individuals, a new study says. ... bioterrorism weapon. Stanford University School of Medicine researchers analyzed ... of three of the people were virtually insensitive to anthrax ...
Cached Medicine News:Health News:Heart disease may be a risk factor for prostate cancer 2Health News:Quality Day Care Predicts Later Parental Involvement in School 2Health News:CD97 gene expression and function correlate with WT1 protein expression and glioma invasiveness 2Health News:CD97 gene expression and function correlate with WT1 protein expression and glioma invasiveness 3Health News:Surgery Effective for Tough-to-Treat Epilepsy 2Health News:Pancreas May 'Taste' Fructose, Hinting at Links to Diabetes 2Health News:Pancreas May 'Taste' Fructose, Hinting at Links to Diabetes 3Health News:Vulnerability to Anthrax Varies Widely: Study 2
... A stethoscope adapter for users of ... acrylic shell type., ,Impressions of ... ,Westone custom products for the ear ... of hearing healthcare providers. These providers ...
Advanced architecture. Small, lightweight and compact. Easy to use....
... bronchoscopy: The HF-compatible V series from Pentax, ... bronchoscopes are measured., ,The HF-compatible series ... FB-19TV, FB-18V and FB-15V models along with ... FB-8V, offer much better image quality thanks ...
... benefits of fibre bronchoscopy: The HF-compatible V ... all other fibre bronchoscopes are measured., ... PENTAX, including the FB-19TV, FB-18V and FB-15V ... and the pediatric FB-8V, offer much better ...
Medicine Products: